Cineverse Corp (CNVS): 1330Xs relative vol.,google partner,hit...

1330Xs relative vol.,google partner,hit zero borrow,profiting now,could be

81vette · 2024-02-14T16:14:31.2930000Z

1330Xs relative vol.,google partner,hit zero borrow,profiting now,could be big potential with institutions in coming weeks(future potential showing in big accumulation right now)

Play Episode

5min

Proactive - Interviews for investors

Actinogen targets $20B Alzheimer’s market with Xanamem

Actinogen Medical Ltd Managing Director and CEO Dr Stephen Gourlay talked with Proactive at the AIM's Small and Midcap conference about the company’s lead asset, Xanamem, and its development in Alzheimer’s disease and depression. Dr Gourlay explained that Xanamem is an oral, once-a-day drug designed to modulate cortisol levels in the brain without interfering with the body’s essential stress response. “We’ve also shown some positive data, you know, phase two and depression as well, which is very exciting because that validates its mechanism,” he said. He outlined the commercial opportunity in both Alzheimer’s and depression. While depression is more prevalent, the Alzheimer's market offers larger potential revenue. He noted that current treatments either have side effects or provide only temporary cognitive improvement, whereas Xanamem could modify the disease course with a better safety profile. Dr Gourlay discussed Actinogen’s recent momentum, including positive results in a depression trial, a number of peer-reviewed publications, and the upcoming interim analysis from its Alzheimer’s trial in Australia and the US. He said, “The upside from a positive Alzheimer’s trial is completely massive… a multi-billion dollar asset.” The company is currently trading below the total investment into drug development, which Dr Gourlay described as a compelling investment case. #Actinogen #Xanamem #AlzheimersResearch #DepressionTreatment #BiotechStocks #ClinicalTrials #Neuroscience #PharmaInnovation #ASX #ProactiveInvestors

Proactive - Interviews for investors

Biome Australia expands global footprint, targets strong growth in clinically proven Probiotics

Biome Australia Managing Director Blair Norfolk joined Steve Darling from Proactive to talk about the company’s expansion strategy and continued growth in clinically validated, condition-specific probiotics. As a leader in live biotherapeutics, Biome Australia has developed probiotics with proven benefits across various health conditions, including mental health, asthma, cardiovascular health, and skin care. The company has over 20 clinical trials validating its products in those areas including the world’s first asthma probiotic, which achieved a 64% reduction in asthma events. Biome’s practitioner-only model ensures that products are recommended by health professionals and sold behind pharmacy counters, contributing to approximately 30% of total sales. While Australia remains the core market, generating over 90% of revenue, Biome is actively expanding into New Zealand, the UK, Ireland, and Canada. Norfolk noted that early results in Canada are ahead of schedule, with further updates expected on the ASX. Instead of launching new products, Biome is focused on expanding use cases for its existing 18-product portfolio, ensuring efficient cash flow management and lower product risk. Biome has emerged as the #2 probiotics brand in Australia’s community pharmacy market by total revenue. Norfolk credited ongoing research and innovation as key drivers of success. Looking ahead, Biome expects a strong close to FY25, fueled by increased demand during cold and flu season, and is on track to deliver its first full-year net profit as part of its Vision 27 strategic plan. #proactiveinvestors #biomeaustralialimited #asx #bio #BlairNorfolk #LiveBiotherapeutics #MentalHealthProbiotics #AsthmaTreatment #PharmaceuticalGrowth #ASXUpdates #NaturalMedicine #TargetedTherapy #PharmacyInnovation #InvestingInHealth #CanadianPharma #ColdAndFluSeason

Proactive - Interviews for investors

Firefly Metals hits high-grade copper-gold at Green Bay

Firefly Metals Ltd managing director Steve Parsons talked with Proactive about the company’s latest drill results from the Green Bay Copper-Gold Project. Parsons highlighted a series of significant intercepts from ongoing infill drilling, including a standout result of 14.2 metres at 7.5% copper equivalent. These results are part of an effort to upgrade the current 24.4 million-ton resource into the indicated category, which is essential for progressing the company’s engineering studies and maintaining ASX compliance. “In some of those infill zones, we’re seeing 50 metres or more at over 2% copper with gold,” Parsons said, underlining the robust nature of the mineralised system. Firefly currently has five underground rigs active, with three focused on infill drilling and two on step-out drilling aimed at further growing the resource. The company expects new results in the coming weeks and is also preparing to commence regional exploration drilling within a ten-kilometre radius of the planned processing plant. Parsons noted the geological potential of the area, stating that VMS high-grade copper-gold systems “typically find more than one,” expressing optimism about upcoming exploration. To stay updated on Firefly Metals Ltd and other mining developments, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future updates. #Copper #Gold #FireflyMetals #GreenBayProject #MiningNews #DrillResults #VMSDeposits #ASX #CopperExploration #ResourceUpdate #ProactiveInvestors

Proactive - Interviews for investors

Nextech3D.ai unveils AI-powered customer service chatbot, ushering new era of customer engagement

Nextech3D.ai CEO Evan Gappelberg joined Steve Darling from Proactive to introduce the company’s latest innovation: an AI-powered customer service chat agent designed to enhance customer interactions and drive sales. This cutting-edge virtual assistant, integrated directly into Nextech3D.ai’s website, features advanced voice technology from Eleven Labs, enabling natural, human-like conversations. The AI chatbot is engineered to streamline customer support with a range of capabilities, including appointment scheduling, a dynamic knowledge base tailored to Nextech’s services, and seamless transitions to live representatives when needed. By leveraging artificial intelligence, Nextech aims to provide a frictionless, efficient, and engaging experience for its customers. Gappelberg emphasized that the adoption of AI chat agents marks a pivotal step in Nextech3D.ai’s evolution into an AI-first technology company, positioning it to compete at the highest level. The chatbot is not just a tool for customer engagement but also a powerful lead generation asset, automating appointment bookings and capturing high-quality leads to optimize service efficiency. By integrating this AI assistant, Nextech ensures that customers receive accurate, brand-aligned responses to their inquiries while maintaining the option for human support when necessary. With this move, Nextech3D.ai reaffirms its commitment to innovation and sets a new standard for AI-driven customer interactions. #nextech3d.al #otcqx #nexcf #cse #ntar #EvanGappelberg #AmazonSellerCentral #3DModeling #AIPhotography #EcommerceInnovation #3DTechnology #LifestylePhotography #ProactiveInterviews #TechInnovation #AmazonPartners#proactiveinvestors #nextech3d.al

Followers	95
Posts	7118
Boards Moderated	3
Alias Born	01/14/2015

Volume:	3
Day Range:
Bid:	3.07
Ask:	3.48
Last Trade Time:	8:16:27 AM EDT
Total Trades:	3

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

CNVS Detailed Quote

Recent CNVS News

More CNVS News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent CNVS News

Go Ad-Free